WO2007037601A1 - Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof - Google Patents
Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereofInfo
- Publication number
- WO2007037601A1 WO2007037601A1 PCT/KR2006/003728 KR2006003728W WO2007037601A1 WO 2007037601 A1 WO2007037601 A1 WO 2007037601A1 KR 2006003728 W KR2006003728 W KR 2006003728W WO 2007037601 A1 WO2007037601 A1 WO 2007037601A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- cells
- present
- seq
- metastasis
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 148
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 134
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 133
- 210000004027 cell Anatomy 0.000 title claims abstract description 90
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 48
- 201000011510 cancer Diseases 0.000 title claims abstract description 36
- 206010027476 Metastases Diseases 0.000 title claims abstract description 29
- 230000009401 metastasis Effects 0.000 title claims abstract description 29
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 27
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 25
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 24
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 23
- 230000012010 growth Effects 0.000 title claims abstract description 20
- 239000013598 vector Substances 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 17
- 239000002157 polynucleotide Substances 0.000 claims abstract description 17
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 17
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 230000001131 transforming effect Effects 0.000 claims description 5
- 241000235648 Pichia Species 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 229920002704 polyhistidine Polymers 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000012360 testing method Methods 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 36
- 206010039073 rheumatoid arthritis Diseases 0.000 description 17
- 102000024905 CD99 Human genes 0.000 description 16
- 108060001253 CD99 Proteins 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 101150016624 fgfr1 gene Proteins 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 201000001441 melanoma Diseases 0.000 description 13
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
- 210000000066 myeloid cell Anatomy 0.000 description 12
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000005012 migration Effects 0.000 description 10
- 238000013508 migration Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 206010003246 arthritis Diseases 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000009545 invasion Effects 0.000 description 8
- 210000001616 monocyte Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000008482 12E7 Antigen Human genes 0.000 description 7
- 108010020567 12E7 Antigen Proteins 0.000 description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 102000016359 Fibronectins Human genes 0.000 description 6
- 108010067306 Fibronectins Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 5
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000003556 vascular endothelial cell Anatomy 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 230000007797 corrosion Effects 0.000 description 4
- 238000005260 corrosion Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000012460 protein solution Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010034464 Periarthritis Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010045240 Type I hypersensitivity Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000005244 lower chamber Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- -1 1 D/D Chemical compound 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010004485 Berylliosis Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- HGJXAVROWQLCTP-YABCKIEDSA-N Chebulagic acid Chemical compound O([C@H]1[C@H]2[C@H]3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OC[C@@H](O1)[C@H]3OC(=O)[C@@H](CC(O)=O)[C@@H]1[C@@H](C(OC=3C(O)=C(O)C=C(C1=3)C(=O)O2)=O)O)C(=O)C1=CC(O)=C(O)C(O)=C1 HGJXAVROWQLCTP-YABCKIEDSA-N 0.000 description 1
- 229920002052 Chebulagic acid Polymers 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000023355 Chronic beryllium disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 101000738349 Homo sapiens CD99 antigen Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 239000007757 Media 199 Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- UGIVASYMZSZAMP-UHFFFAOYSA-N chebulagic acid Natural products OC1C2c3c(OC1=O)c(O)c(O)cc3C(=O)OC4C(OC(=O)c5cc(O)c(O)c(O)c5)OC6COC(=O)c7cc(O)c(O)c(O)c7c8c(O)c(O)c(O)cc8C(=O)OC4C6OC(=O)C2(O)C(=O)O UGIVASYMZSZAMP-UHFFFAOYSA-N 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 201000009803 desquamative interstitial pneumonia Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000058100 human CD99 Human genes 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000005158 lymphoid interstitial pneumonia Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000032954 positive regulation of cell adhesion Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000024155 regulation of cell adhesion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000002419 toxicodendron dermatitis Diseases 0.000 description 1
- 229960001814 trypan blue Drugs 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- control peptide is a peptide consisting of EEFD.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, or a fusion protein thereof. The present invention also provides a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases including the polypeptide or a fusion protein thereof. The present invention also provides a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof.
Description
Description
POLYPEPTIDE INHIBITING TRANSMIGRATION OF
LEUKOCYTES OR GROWTH AND/OR METASTASIS OF
CANCER CELLS, AND FUSION PROTEIN THEREOF
Technical Field
[1] The present invention relates to a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, or a fusion protein thereof. The present invention also relates to a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. The present invention also relates to a pharmaceutical composition for the prevention or treatment of inflammatory diseases including the polypeptide or a fusion protein thereof. The present invention also relates to a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof. Background Art
[2] An inflammatory response is known as a protective response of living organism for rehabilitating the structures and functions of tissues damaged by infection, trauma, etc. Mobilization of leukocytes to a focus of inflammation is critical for the rapid resolution of infections and restoration of tissue damages resulting from a variety of injuries. However, a misdirected or prolonged inflammatory response causes damage to the body's tissues or diseases. For example, inflammatory diseases are caused by bacterial or viral infection, e.g., cerebrospinal meningitis, enteritis, dermatitis, uveitis, encephalitis, or adult respiratory distress syndrome, or non-infectious factors, e.g., trauma, autoimmune diseases, or organ transplantation rejection. Inflammatory diseases are classified into acute and chronic inflammatory diseases according to symptoms or pathological features. Acute inflammation such as allergy or bacterial/ viral infection is manifested as local signs such as a change in bloodstream, blood vessel size, and vascular permeability, and the recruitment of leukocytes. In contrast, a main pathological feature of chronic inflammation such as rheumatoid arthritis, artherosclerosis, chronic kidney infection, or hepatocirrhosis is a continuous emigration of macrophages, lymphocytes, or plasma cells into foci of inflammation due to recurrence of inflammatory factors, thereby causing a long-lasting inflammatory response.
[3] In order to induce an inflammatory response, the emigration of leukocytes into inflammation foci is an essential event. Many cell adhesion molecules are implicated in the emigration of leukocytes. That is, the emigration of leukocytes includes a rolling
stage in which leukocytes are mobilized to the blood vessels of inflamed sites by chemokine secreted from the inflamed sites and then rolled on surfaces of vascular endothelial cells while reducing the velocity of cell movement; an adhesion stage in which the leukocytes stops rolling and are firmly adhered to the vascular endothelial cells; and a transmigration stage wherein the leukocytes migrate through capillary vessels and basement membranes. The final stage, i.e., the transmigration stage is also called "diapedesis" or "transendothelial migration".
[4] Cancer cells induced by carcinogens proliferate rapidly relative to normal cells, thereby forming tumor masses, invading surrounding tissues, and interfering with normal body functions. Cancer cells bring nutrients and oxygen by inducing an- giogenesis, and metastasis thereof is also caused by angiogenesis. Although cancer cells grow infinitely at specific sites, they can also leave the sites from which they originated, migrate to and grow in new sites, whose process is called "metastasis". Metastasis involve several key steps: conversion of cancer cells to migratory mesenchymal cells, dissociation of the mesenchymal cells from the original tumor sites, invasion into and spread through surrounding connective tissues and capillary vessels, migration through blood vessels, escape from the blood vessels, migration through connective tissues, and proliferation in secondary sites.
[5] Expression and activation of cell adhesion molecules on surfaces of tumor cells play a very important role in tumor metastasis (Zetter, B. R. (1993). Adhesion molecules in tumor metastasis. Semin Cancer Biol. 4: 219). Tumor metastasis is induced by regulating the expression pattern and activity of cell adhesion molecules on surfaces of tumor cells. In order to understand the metastasis of tumor cells, it is prerequisite to understand cell adhesion molecules and substances for regulating the expression and functions of the cell adhesion molecules (Bailly, M., Yan, L., Whitesides, G. M., Condeelis, J. S., and Segall, J. E. (1998). regulation of Protusion Shape and Adhesion to the sustratum during chemoacic esponses of mammalian carcinoma cells. Exp Cell Res. 241: 285; Frisch, S. M., Vuori, K., Ruoslahti, E., and Chan-HuL, P. (1996). Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134: 793; and Hannigan, G. E., Leung-Hagesteijn, C. , Fitz-Gibbon, L., Coppolino, M. G., Radeva, G., Filmus, J., Bell, J. C, and Dedhar, S. (1996). Regulation of cell adhesion and anchorage-dependent growth by a new βl-integrin-linked protein kinase. Nature 379: 91).
[6] Meanwhile, the present inventors have disclosed that CD99 (MIC2) molecule, which is one of the transmembrane proteins, regulates an intercellular adhesion by regulating a cell surface expression of LFA-I (Hahn, J. H., Kim, M. K., Choi, E. Y., Kim, S. H., Sohn, H. W., Ham, D. I., Chung, D. H., Kim, T. J., Lee, W. J., Park, C. K., Ree, H. J., and Park, S. H. (1997) CD99 (MIC2) regulates the LFA-
1/ICAM-l -mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J. Immunol. 159: 2250). CD99 is a type I transmembrane protein composed of a glycosylated extracellular domain, a transmembrane domain, and a short intracellular domain (Banting, G. S., Pym, B., Darling, S. M., and Goodfellow P. N. (1989). The MIC2 gene product: epitope mapping and structural prediction analysis define an integral membrane protein. MoI. Immunol. 26: 181). Although there has not been much research about the function of the CD99 molecule, it has been presumed that the CD99 molecule is associated with cell adhesion, on the basis of the observations that the engagement of the CD99 molecule with anti-CD99 monoclonal antibody induces homotypic cell aggregation of various lymphoid cell lines as well as double-positive thymocytes (Bernard, A., Aubrit, F., Raynal, B., Pham, D., and Boumsell, L. (1988). A T cell surface molecule different from CD2 is involved in spontaneous rosette formation with erythrocytes. J Immunol 140: 1802; and Bernard, G., Zoccola, D., Deckert, M., Breittmayer, J., Aussel, C, and Bernard. A.(1995). The E2 molecule (CD99) specifically triggers homotypic aggregation of CD4+ CD8+ thymocytes. J. Immunol. 154: 26).
[7] The present inventors have found that CD99 is involved in the migration of monocytes through connective tissues (Kim YK., 2004. Regulation of MMP-9 gene expression by CD99 type II in the monocytes. Kangwon National University). The present inventors have also disclosed that when CD99 is activated, the function of β integrin is altered, thereby preventing the adhesion of cancer cells onto extracellular matrices (ECMs). This suggests that CD99 may be involved in metastasis of cancer cells (Suh JS., 2001. Control of invasiveness of human breast carcinoma cell line MCF-7 by CD99 molecule. Kangwon National University). In addition, Muller WA et al. have disclosed that inflammatory diseases can be cured by inhibiting the CD99-mediated transmigration of leukocytes (Schenkel AR, Mamdouh Z, Chen X, Lieman RM, Muller WA (2002) CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 3:143; and US. Patent Publication No. 2003/0211099). Disclosure of Invention Technical Problem
[8] The present inventors have found that a polypeptide having an amino acid sequence derived from CD99 can prevent the transmigration of leukocytes or the growth and/or metastasis of cancer cells.
[9] Therefore, the present invention provides a polypeptide derived from CD99, inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, and a fusion protein thereof.
[10] The present invention also provides a polynucleotide encoding the polypeptide and a vector including the polynucleotide.
[11] The present invention also provides a transformant obtained by transforming a host cell with the vector.
[12] The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases, including the polypeptide or its fusion protein as an active ingredient and a pharmaceutically acceptable carrier.
[13] The present invention also provides a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells, including the polypeptide or its fusion protein as an active ingredient and a pharmaceutically acceptable carrier. Technical Solution
[14] In accordance with an aspect of the present invention, there is provided a polypeptide consisting of 4 - 130 amino acids derived from the peptide of SEQ ID NO: 1, said polypeptide comprising an amino acid sequence from position 94 to position 97 of SEQ ID NO: 1; wherein said polypeptide inhibits transmigration of leukocytes or growth and/or metastasis of cancer cells.
[15] In accordance with another aspect of the present invention, there is provided a fusion protein wherein a polyhistidine (poly-His) region is fused to the polypeptide.
[16] In accordance with still another aspect of the present invention, there is provided a polynucleotide encoding the polypeptide.
[17] In accordance with still another aspect of the present invention, there is provided a vector comprising the polynucleotide encoding the polypeptide.
[18] In accordance with still another aspect of the present invention, there is provided a transformant obtained by transforming a host cell with the vector.
[19] In accordance with yet another aspect of the present invention, there is provided a pharmaceutical composition for the prevention or treatment of inflammatory diseases, comprising the polypeptide or its fusion protein as an active ingredient and a pharmaceutically acceptable carrier.
[20] In accordance with a further aspect of the present invention, there is provided a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells, comprising the polypeptide or its fusion protein as an active ingredient and a pharmaceutically acceptable carrier. Brief Description of the Drawings
[21] FTG. 1 illustrates the structures of polypeptides as set forth in SEQ ID NOs: 2-9;
[22] FIGs. 2 and 3 are graphs illustrating effects of polypeptides of the present invention on the transmigration of a human monocyte cell line, U937;
[23] FIG. 4 is a graph illustrating effects of polypeptides of the present invention on
rheumatic inflammation of mice having collagen-induced arthritis; [24] FlG. 5 shows the degree of corrosion of articular cartilages of a control group and a test group treated with a polypeptide of the present invention; [25] FlG. 6 is a graph illustrating cell numbers of transmigrated lymphocytes and myeloid cells in the spleens of a control group and a test group treated with a polypeptide of the present invention; [26] FlG. 7 is a graph illustrating cell numbers of T cells (CD3+), B cells (CD19+), and myeloid cells (CDlIb+, Gr-I+) migrated into the joint spaces of a control group and a test group treated with a polypeptide of the present invention; [27] FlGs. 8 and 9 are graphs illustrating expression levels of TNF-α and IFN-γin the sera of a control group and a test group treated with a polypeptide of the present invention; [28] FlGs. 10 and 11 are graphs illustrating effects of polypeptides of the present inventi on on adhesion of HUVEC (Human Umbilical Vein Endothelial Cell) to fibronectin; [29] FlG. 12 is inverted microscopic images showing effects of polypeptides of the present invention on bFGF-induced tube formation; [30] FlG. 13 is images showing degree of development of melanoma (A) and degree of angiogenesis (B) in a control group and a test group treated with a polypeptide of the present invention; [31] FlG. 14 is a graph illustrating melanoma tumor volumes in a control group and a test group treated with a polypeptide of the present invention; [32] Fig. 15 is a graph illustrating transendothelial migration assays for MCF-7 human breast carcinoma cells after administration of a polypeptide of the present invention; [33] FlG. 16 is a graph illustrating invasion assay for MCF-7 human breast carcinoma cells after administration of a polypeptide of the present invention; [34] FlG. 17 is images (A) showing nodules of melanoma cells that have spread to the lungs and liver through transmigration after administration of a polypeptide of the present invention and a graph (B) illustrating the number of the nodules.
Mode for the Invention [35] Throughout the specification, the term "inflammatory diseases" include acute and/or chronic inflammatory diseases, e.g., rheumatoid arthritis, adhesive capsulitis, sinovitis, coxarthritis, osteoarthritis, osteoporosis, periarthritis, multiple sclerosis, osteomyelitis, systemic lupus erythematosus, polymyalgia rheumatica(PMR), Sjogren's Syndrome, progressive systemic sclerosis(scleroderma), ankylosing spondylitis, polymyositis, der- matomyositis, pemphigus, pemphigoid, Type I diabetes mellitus, myasthenia gravis,
Hashimoto's thyroditis, Graves' disease, Goodpasture's disease, mixed connective tissue disease, sclerosing cholangitis; inflammatory bowel disease such as Crohn's
Disease or ulcerative colitis, inflammatory dermatoses; inflammatory respiratory diseases such as usual interstitial pneumonitis(UIP), lymphoid interstitial pneumonia, giant cell interstitial pneumonia, cellular interstitial pneumonia, desquamative interstitial pneumonia, asbestosis, silicosis, berylliosis, talcosis, pneumoconiosis, Adult Respiratory Distress Syndrome, extrinsic allergic alveolitis; immediate hypersensitivity reactions such as asthma or hayfever; sarcoidosis, Wegener's granulomatosis, various angiitis, chronic active hepatitis, delayed-type hypersensitivity reactions such as poison ivy dermatitis, cutaneous allergies, psoriatic arthritis, Reiter's syndrome, immediate hypersensitivity reactions, rheumatic fever, acute or chronic glomerulonephritis, acute exacerbations, pyelonephritis, cellulitis, cystitis, acute cholecystitis, inflammatory aortic aneurysm, atherosclerosis, Still's diseas), Parkinson's disease, Alzheimer's disease. A polypeptide or fusion protein of the present invention can also be administered to patients suffering from diseases involving inflammatory diseases, e.g., reperfusion injuries, autoimmune diseases, organ transplantation rejection or tissue allograft organ rejection, etc. Thus, the "inflammatory diseases" as used herein are meant to comprehend diseases involving inflammatory diseases. A polypeptide or fusion protein of the present invention can be used in rheumatoid arthritis, osteoporosis, respiratory inflammation, autoimmune diseases, and/or organ transplantation rejection, particularly preferably, rheumatoid arthritis, autoimmune diseases, and/or organ transplantation rejection.
[36] The present inventors have made searches for ligand(s) capable of activating a
CD99 molecule having an amino acid sequence as set forth in SEQ ID NO: 1. In view that CD99 itself acts as a ligand recognizing a CD99 molecule that is a transmembrane protein, ligands of various lengths were made from CD99 molecule and searches were made using the ligands.
[37] Surprisingly, the present inventors found that polypeptides having certain amino acid sequences derived from CD99 could show anti-inflammatory activity by blocking the transmigration of leukocytes through high-affinity binding to vascular endothelial cells and leukocytes. When the polypeptides were injected into inflamed sites of mice with arthritis, an arthritis index and the transmigration of lymphocytes and granulocytes related thereto were significantly reduced, as compared with control mice. Those results show that the polypeptides have preventive or treatment activity for inflammatory responses.
[38] Furthermore, the present inventors found that polypeptides having the amino acid sequences derived from CD99 could inhibit the growth and/or metastasis of cancer cells by inhibiting angiogenesis through high-affinity binding to surfaces of vascular endothelial cells and inhibiting the migration and transmigration of cancer cells through binding to the cancer cells. When the polypeptides were administered to
affected sites of mice with melanoma, tumor growth and metastasis were significantly reduced as compared with control mice. Those results show that the polypeptides have inhibitory activity for the growth and/or metastasis of cancer cells.
[39] The present invention provides a polypeptide consisting of 4 - 130 amino acids derived from the peptide of SEQ ID NO: 1, said polypeptide comprising an amino acid sequence from position 94 to position 97 of SEQ ID NO: 1; wherein said polypeptide inhibits transmigration of leukocytes or growth and/or metastasis of cancer cells. The polypeptide may be selected from the group consisting of polypeptides as set forth in SEQ ID NOs: 2-8. More preferably, the polypeptide may be selected from the group consisting of polypeptides as set forth in SEQ ID NOs: 9-11 and 13-16.
[40] The present invention also provides a fusion protein wherein a polyhistidine
(poly-His) region is fused to the polypeptide. The poly-His region, which is a tag polypeptide, can be used for the separation and purification of the polypeptide of the present invention by binding to a histidine binding resin. In the fusion protein of the present invention, the poly-His region may have an amino acid sequence as set forth in SEQ ID NO: 17.
[41] The present invention also provides a polynucleotide encoding the polypeptide. The polynucleotide can be prepared using a known method in the art. The polynucleotide may have a nucleotide sequence selected from the group consisting of nucleotide sequences as set forth in SEQ ID NOs: 18-20 and 22-25.
[42] The present invention also provides a vector comprising the polynucleotide encoding the polypeptide. Various known cloning vectors, e.g., pPICZα A, B, or C (Invitrogen, U.S.A.), may be used as a cloning vector. Preferably, a vector including DNA encoding a poly-His region, e.g., a pET28a(+) vector (Novagen, U.S.A.) may be used as a cloning vector. The vector of the present invention can be constructed by inserting the polynucleotide encoding the polypeptide into a cloning vector with an appropriate restriction enzyme site using a method commonly known in the art. The vector of the present invention may be directly used in a gene therapeutic composition for the purpose of gene therapy or may be used in the production of transformants.
[43] The present invention also provides a transformant obtained by transforming a host cell with the vector. The host cell is not particularly limited as long as the polypeptide can be effectively expressed. Preferably, the host cell may be selected from microorganisms belonging to the genus Escherichia (e.g., Escherichia coli), the genus Pichia (e.g., X-33 Pichia; Invitrogen, U.S.A.), etc.
[44] The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases, comprising the polypeptide or its fusion protein as an active ingredient and a pharmaceutically acceptable carrier.
[45] The present invention also provides a pharmaceutical composition for inhibiting the
growth and/or metastasis of cancer cells, comprising the polypeptide or its fusion protein as an active ingredient and a pharmaceutically acceptable carrier.
[46] The pharmaceutical compositions of the present invention may include excipients such as lactose or corn starch, lubricants such as magnesium stearate, currently available emulsifiers, suspending agents, buffers, isotonic agents, etc. The pharmaceutical compositions of the present invention can be administered orally or par- enterally. Preferably, the pharmaceutical compositions of the present invention can be formulated into parenteral dosage forms. For intramuscular, intraperitoneal, subcutaneous, or intravenous administration, a sterilized solution of an active ingredient is generally prepared. In this case, the sterilized solution may include a buffer to achieve a desired pH value. With respect to formulations for intravenous administration, an isotonic agent may be used to render the formulations isotonic. The pharmaceutical compositions of the present invention can be formulated into aqueous solutions including a pharmaceutically acceptable carrier such as a saline of pH 7.4. The aqueous solutions can be introduced into a patient's intramuscular blood stream by local bolus injection.
[47] The pharmaceutical composition of the present invention can be administered to patients who suffer from inflammatory diseases, solid cancer (breast cancer, gastric cancer, large bowel cancer, colon cancer, rectal cancer, pancreatic cancer) or lymphoma at a daily dosage of about 0.01 to 10 mg/kg. An adequate dosage is generally determined according to age, body weight, and conditions of a patient.
[48] Hereinafter, the present invention will be described more specifically by the following working examples. However, the following working examples are provided only for illustrations and thus the present invention is not limited to or by them.
[49]
[50] Example 1: synthesis of polypeptides
[51] cDNA fragments of SEQ ID NOs: 18-22 encoding respective polypeptides of SEQ
ID NOs: 9-13 were inserted into pET28a(+) vectors carrying cDNAs encoding the Fc regions of human immunoglobulin to produce five types of pET28a-hCD99-Fc vectors. That is, the cDNA fragments of SEQ ID NOs: 18-22 were isolated by PCR, digested with EcoRI, and inserted into the EcoRI sites of pET28a(+) vectors with ligation enzymes to produce the five types of the pET28a-hCD99-Fc vectors.
[52] Colonies obtained by transforming BL21(DE3) cells with the expression vectors, pET28a-hCD99-Fc, were cultured in LB media for about 4-6 hours. When the absorbance (A600) of the cultures reached 0.4-0.6, protein expression was induced by isopropyl β-D-1-thiogalactopyranoside (IPTG) (1.4 mM) for 7-9 hours. The cells were precipitated by centrifugation, washed with phosphate buffered saline (PBS), and precipitated to remove impurities from the media. Fractions were analyzed by SDS-PAGE
gel to check protein expression.
[53] For purification of expressed proteins, an 8M urea buffer (8M urea, 0.01M Tris-Cl,
0.1M NaH PO ) was used. The pH of the urea buffer was adjusted to 8.0, 6.3, 4.5, etc. according to a purification step. The cells were lysed with a pH 8.0 urea buffer containing protease inhibitors (1 mM PMSF, 10 D/D leupeptin, 1 D/D, pepstatin, 1 D/D aprotinin) and centrifuged at 13,000 rpm for 20 minutes at 4 °C. The supernatants were mixed with histidine (His)-binding resins (Ni-NTA His Bind Resins, Novagen, U.S. A.) in a 1 D Eppendorf tube, and the mixtures were incubated at 4 °C for 16 hours to induce the binding of histidine residues of the expressed proteins with the His-binding resins. The reaction solutions were centrifuged, the supernatants were discarded, and the pellets were washed with a pH 6.3 urea buffer. The protein was then eluted with a pH 4.5 urea buffer, dialyzed against PBS, and stored in aliquots in a cold store.
[54] Polypeptides of SEQ ID NOs: 14-16 were synthesized with an automatic peptide synthesizer (PeptrEx-R48, Peptron, Daejeon, Korea) using a FMOC solid-phase method. The synthesized polypeptides were purified and analyzed by reverse-phase high-performance liquid chromatography (reverse-phase HPLC) (Prominence LC- 20AB, Shimadzu, Japan) using a C18 analytical RP column (Shiseido capcell pak), and isolated using a mass spectrometer (HP 1100 Series LC/MSD, Hewlett-Packard, Roseville, U.S.A.). For optimization of Experimental Examples 2, 3, 8, and 11 using mice as an experimental animal, a polypeptide derived from the mouse CD99 (SEQ ID No: 26) was also synthesized with the same methods in the above. The polypeptide of SEQ ID No: 26 corresponds to the polypeptide of SEQ ID No: 14 derived from human CD99.
[55] The structures of polypeptides as set forth in SEQ ID NOs: 9-16 are illustrated in
FIG. 1.
[56]
[57] Example 2: preparation of polypeptide-containing compositions
[58] The polypeptides of SEQ ID NOs: 9-13 were dissolved in PBS to a concentration of
3 D/100 D. Also, the polypeptides of SEQ ID NOs: 14-16 and 26 were dissolved in dimethylsulfoxide (DMSO) to a concentration of 3 D/D, and a saline solution was added thereto so that the concentration of each polypeptide was 20 D, 40 D, 80 D, or 100 D based on the volume (100 D) of the final solution. The resultant protein solutions were used in the following experimental examples.
[59]
[60] Experimental Example 1: tests for inhibitory activity of polypeptides of the present invention against transmigration of monocytes
[61] Human Umbilical Vein Endothelial Cells (HUVECs) were cultured in the upper compartments of Boy den chambers. The supernatants were removed, and human
monocytes (U937), which had been untreated or treated with the compositions prepared in Example 2, were seeded at 5 x 105 cells/chamber. At this time, a culture including a chemo-attractant (a supernatant obtained by centrifugation of a culture obtained after culturing NIH/3T3 mouse fibroblasts in serum-free DMEM containing 0.005% vitamin C and 0.1% Bovine Serum Albumin (BSA) for 16 hours) was placed in the lower compartments of the chambers to induce the invasion of the monocytes. The chambers were incubated for 6 hours, and the number of the cells migrated to the lower compartments was measured. The test was repeated five times, and the results are illustrated in FIGs. 2 and 3. In FIG. 3, the "control peptide" is a peptide consisting of EEFD.
[62] Referring to FIGs. 2 and 3, the number of migrated monocytes in the test groups treated with polypeptides according to the present invention was significantly reduced (about 2/3 reduction) as compared with that in the control group.
[63]
[64] Experimental Example 2: tests for inhibitory activity of polypeptides of the present invention against arthritis
[65] Effects of polypeptides of the present invention on rheumatoid arthritis (RA), one of representative inflammatory diseases, were tested. Type II collagen (10 mg/kg) was injected into mice (8-12 weeks old) to induce RA. A solution of a polypeptide of SEQ ID NO: 26 (40 or 80 D) in a saline solution (100 D) was intraperitoneally administered to the mice with RA at 2-day intervals (100 D for each) for four weeks. As control groups, a saline solution (100 D) or a solution of methotrexate (MTX, 100 D) used as an antiinflammatory agent in a saline solution (100 D) was intraperitoneally administered to the mice with RA.
[66] The onset and severity of arthritis in each experimental group were visually determined, and the arthritis index was measured using a method known in the art (SI Lee, PM Hyun, SH Kim, KS Kim, SK Lee, BS Kim, PJ Maeng, and J-S Lim (2005) Suppression of the Onset and Progression of Collagen-Induced Arthritis by Chebulagic Acid Screened From a Natural Product Library. Arthritis Rheum 52: 345). The results are illustrated in FIG. 4. In FIG. 4, CIA represents collagen-induced arthritis. Referring to FIG. 4, in the test groups treated with the polypeptide of the present invention, arthritis indices began to decrease 2 weeks after the polypeptide treatment. At 4 weeks after the polypeptide treatment, the arthritis indices were reduced to about 1/3 of those of the control groups.
[67] Meanwhile, the degree of corrosion of articular cartilages of normal mice with no
RA and the above CIA mice was measured. That is, the knee joint tissues of the hind legs of the normal mice with no RA, saline-treated CIA mice, MTX-treated CIA mice, and CIA mice treated with a solution of a polypeptide of SEQ ID NO: 26 (80 D) in a
saline solution (100 D) were harvested. The harvested tissues were fixed in 10% formalin, decalcified with 5% formic acid, processed into paraffin blocks, cut into 5 D sections, and stained with haematoxylin and eosin or Masson's trichrome, and examined with a microscope (at 20Ox magnification). The results are shown in FlG. 5.
[68] Referring to FlG. 5, severe corrosion and invasion of leukocytes were observed in the articular cartilages of the CIA mice, as compared with the normal mice. In contrast, corrosion of articular cartilages and invasion of leukocytes in the CIA mice treated with the polypeptide of SEQ ID NO: 26 according to the present invention were diminished to the extent that was observed in the normal mice and the MTX-treated CIA mice.
[69]
[70] Experimental Example 3: tests for inhibitory activity of polypeptides of the present invention against transmigration of lymphocytes and myeloid cells in the spleens
[71] A polypeptide of SEQ ID NO: 26 (40 D/100D) was intraperitoneally administered to mice with RA, which had been induced in the same manner in Experimental Example 2, at 2-day intervals for 4 weeks. Normal mice, saline-treated RA mice with intraperitoneal injection of a saline solution, and MTX-treated RA mice with intraperitoneal injection of a solution of MTX (100 D) in a saline solution (100 D) were used as control groups. Spleen tissues were harvested from the mice of all the experimental groups and washed with RPMI 1640 media, and single cells were isolated. After the total number of the single cells were counted, the single cells were stained with monoclonal antibodies (anti-CD3\ CD4+, CD8+, CDlIb+, CD19\ CD69+, Gr-I+) capable of labeling T cells (CD3+, CD4+, CD8+), activated T cells (CD3+, CD69+), B cells (CD19+), and myeloid cells (CDlIb+, Gr-I+), and flow cytometry analysis was performed. The number of lymphocytes and myeloid cells migrated to joint spaces was measured by determining the number of the T cells, the activated T cells, the B cells, and the myeloid cells per total cell number, and the results are illustrated in FlG. 6.
[72] Referring to HG. 6, the migrated cell numbers for the T cells (CD3+, CD4+, CD8+), the activated T cells (CD3+, CD69+), the B cells (CD19+), and the myeloid cells (CDl Ib+, Gr-I+) in the test group treated with the polypeptide according to the present invention were similar to those of the MTX-treated group, and were reduced to about 2/3 of those of the saline-treated group.
[73]
[74] Experimental Example 4: tests for inhibitory activity of polypeptides of the present invention against migration of T cells (CD3+), B cells (CD19+), and myeloid cells (CDlIb+, Gr-I+) into the joint spaces
[75] As well known, when inflammation develops in joints, lymphocytes and myeloid
cells of different differentiation stages invade joint spaces. Thus, effects of polypeptides according to the present invention on invasion of lymphocytes and myeloid cells into joint spaces were tested.
[76] The polypeptide of the present invention, a saline solution, or MTX was administered to RA mice in the same manner as in Experimental Example 3, and synovial fluid was obtained from the joint spaces of the mice of all the experimental groups. After the total cell number in the synovial fluid was counted, flow cytometry analysis was performed in the same manner as in Experimental Example 3 to measure the number of T cells (CD3+), B cells (CD19+), and myeloid cells (CDlIb+, Gr-I+) migrated to the joint spaces. The results are illustrated in FIG. 7.
[77] Referring to FIG. 7, the number of T cells (CD3+, CD4+, CD8+), B cells (CD19+), and myeloid cells (CDl Ib+, Gr-I+) migrated to joint spaces in the polypeptide-treated group according to the present invention was similar to that of the MTX-treated group and was reduced to about 50-70% of that of the saline-treated group.
[78]
[79] Experimental Example 5: tests for inhibitory activity of polypeptides of the present invention against expression of TNF-αand IFN-γ
[80] When inflammation occurs, invasion of T cells into peripheral lymph nodes increases, and the expression levels of TNF-αand INF-γwhich are secreted from the T cells also increase. Thus, effects of polypeptides according to the present invention on the expression of TNF-αand INF-γwere tested.
[81] RA was induced in mice in the same manner as Experimental Example 2, and a saline solution, MTX, or a polypeptide according to the present invention was administered to the RA mice. Then, sera were isolated from all the experimental groups, and the expression levels of TNF-αand INF-γwere measured using ELISA. The results are illustrated in FIGs. 8 and 9.
[82] Referring to FIGs. 8 and 9, the expression levels of TNF-αand INF-γ in the polypeptide-treated group according to the present invention were similar to those of the MTX-treated group and were reduced to about 50% of those of the saline-treated group.
[83]
[84] Experimental Example 6: tests for inhibitory activity of polypeptides of the present invention against adhesion of HUVEC to extracellular matrix
[85] Effects of polypeptides of SEQ ID NOs: 9-16 on adhesion of HUVEC to fibronectin were tested.
[86] Each well of a 96-well culture plate was coated with fibronectin, a component of extracellular matrix, for 6 hours under UV light, and then blocked with 1% heat- inactivated BSA for 1 hour. HUVEC cells (5 x 10 ) were dispensed into each well, and
then the protein solution prepared in Example 2 was added to the well. After incubation in 5% CO at 37 °C for 1 hour, the cells were gently washed three times with PBS, and then detached using trypsin-EDTA and stained with a trypan-blue solution. The number of the cells was determined using a hemacytometer. The results are illustrated in FIGs. 10 and 11.
[87] Referring to FIGs. 10 and 11, in the test groups treated with the polypeptides of the present invention, the number of HUVECs adhered to fibronectin was reduced by about 10-40% relative to a control group. However, in the test group treated with the polypeptide of SEQ ID NO: 12 including no amino acids at positions 94-97 of SEQ ID NO: 1, the degree of adhesion of HUVECs to fibronectin was similar to that of the control group. Thus, it is anticipated that polypeptides of the present invention including peptides at positions 94-97 of SEQ ID NO: 1 can inhibit angiogenesis.
[88]
[89] Experimental Example 7: tests for inhibitory activity of polypeptides of the present invention against in vitro tube formation
[90] Interactions of basement membrane components of blood vessels with vascular endothelial cells play an important role in formation and maintenance of new blood vessels. Thus, effects of polypeptides of the present invention on tube formation were evaluated.
[91] HUVECs were plated at a density of 8 x 104 cells/well to each well of 24- well culture plates coated with Matrigel. The protein solution including the polypeptide of SEQ ID NO: 9 (30 D/D) prepared in Example 2, secondary antibody (Goat anti-mouse IgG; Dinona, Korea), or a mixture thereof was added to the wells, and the cells were cultured in media 199 containing 20% fetal bovine serum (FBS), penicillin (100 units/ D), streptomycin (100 WIW), bFGF (3 ng/D), and heparin (5 units/D) in aiβ&bator maintained at 5% CO partial pressure and a temperature of 37 °C for 24 hours. Formation of new blood vessels was examined using an inverted microscope (at 50x magnification), and the results are shown in FIG. 12.
[92] Referring to FIG. 12, when HUVECs were treated with the protein solution including the polypeptide of the present invention, tube formation was significantly reduced.
[93]
[94] Experimental Example 8: tests for inhibitory activity of polypeptides of the present invention against in vivo tumor development and angiogenesis
[95] B16-F10-Luc-G5 (mouse melanoma cell line, Xenogen, U.S.A.) was injected into the subcutaneous fat tissues of the backs of 10 male nude mice (5 weeks old) (1.5 x 10 cells/mouse). At 48 hours after the injection, the mice were divided into five mice for a test group and five mice for a control group. In the test group, a polypeptide (100 D) of
SEQ ID NO: 26 was intraperitoneally administered to each mouse at a 48-hour intervals. Tumor cells were injected into the test group and the control group, and from 12 days after the injection of the tumor cells, a tumor volume was measured. The tumor volume was calculated by the formula: (L x W)2 x H x 0.5 where L, W, and H are respectively the length, width, and height of tumor.
[96] At 14 days after the injection of the tumor cells, tumor tissues were excised from the mice, fixed in 4% paraformaldehyde, washed with water, processed into paraffin blocks, cut into 5 D standard frontal sections, and stained with haematoxylin and eosin, and examined with a microscope (at 4Ox magnification) to compare the degree of an- giogenesis.
[97] FIG. 13 is images showing the degree of development of melanoma (A) and the degree of angiogenesis (B) in the control group and the test group treated with the polypeptide of the present invention. Referring to FIG. 13, in the test group treated with the polypeptide of the present invention, the development of melanoma and angiogenesis were significantly reduced as compared with those of the control group.
[98] FIG. 14 is a graph illustrating melanoma tumor volumes in the control group and the test group treated with the polypeptide of the present invention. Referring to FIG. 14, in the test group treated with the polypeptide of the present invention, melanoma volume at 12 days after the injection of the tumor cells was reduced to about 1/6 of that of the control group.
[99]
[100] Experimental Example 9: tests for inhibitory activity of polypeptides of the present invention against in vitro transmigration of cancer cells
[101] Transendothelial migration assays for MCF-7 human breast carcinoma cells were performed in polycarbonate transwell inserts (8-D pore; Costar,Corning, NY) coated with HUVECs and grown as a monolayer for 24 hours. MCF-7 cells were resuspended in serum-free RPMI- 1640and were preincubated with 10 Dof a control peptide consisting of EEFD or 10 D of a peptide of SEQ ID NO: 16 for 1 hour before plating. HUVEC cells were also treated as described above at the same time.Typically, 5 X 105 MCF-7 cells were seeded in the upper compartment, and chemo-attractant (described in Experimental Example 1) was placed in the lower compartment. After 6 hours at 37 °C, the number of MCF-7 cells that had migrated through the monolayer was determinedby direct counting.
[102] FIG. 15 is a graph illustrating the number of transmigrated cells in the experiment described above. Referring to FIG. 15, the number of transmigrated MCF-7 cells in the test groups was reduced to about 60% of that in the control group. Taking into consideration that transmigration is essential for migration of cancer cells into organs through blood vessels, it is anticipated that polypeptides of the present invention can
effectively inhibit the migration of cancer cells. [103] [104] Experimental Example 10: tests for inhibitory activity of polypeptides of the present invention against invasion of cancer cells
[105] Cell migration was measured using a Transwell migration apparatus(Costar, Inc.,
Cambridge, United Kingdom). The filters (8-D pore size) were coated with lmg/ml fi- bronectinsolution on top surface. MCF-7 cells were treated with a polypeptide of SEQ ID NO: 14 (10 D, 50 D, 100 D), incubated in a 5% Cfficubator at 37 °C for 1 hour, and then washed with serum-free RPMI- 1640. MCF-7 cells (2.4 x 10 cells) were loaded to the upper chamber of the Transwell, whereas chemo-attractant described above were loaded into the lowerchamber. Cells migrated into the lower chambers of the Transwell were counted three times at 24-hour intervals, and then the results were stastically analyzed.
[106] FIG. 16 is a graph illustrating the number of the human breast cancer cells that have invaded fibronectin after administration of the polypeptide of the present invention. Referring to FIG. 16, in the test groups treated with the polypeptide of the present invention, the invasion rate of the human breast cancer cells was reduced by about 50% relative to that of a control group treated with a peptide consisting of EEFDDAEEFDD. Taking into consideration that cancer cells from blood vessels invade basement membranes or surrounding connective tissues and then spread to secondary sites, it is anticipated that polypeptides of the present invention can effectively inhibit the metastasis of cancer cells.
[107]
[108] Experimental Example 11: tests for inhibitory activity of polypeptides of the present invention against in vivo transmigration of cancer cells
[109] B16-F10-Luc-G5 cells (mouse melanoma cell line, Xenogen, U.S.A.) were injected into the tail veins of 10 nude mice (5 weeks old). The nude mice were divided into five mice for a control group and five mice for a test group. The control group was injected with a mixture of PBS with a peptide consisting of EEFDDAEEFDD (control peptide) and the test group with a mixture of PBS with 100 D of a peptide of SEQ ID NO: 26. The control peptide and the peptide of SEQ ID NO: 26 were intraperitoneally administered to the control group and the test group, respectively, at 2-day intervals for 15 days. Then, the nude mice were dissected and the lungs and livers were excised from the nude mice. Tumor nodules were counted.
[110] FIG. 17 is images (A) showing melanoma nodules that have spread to the lungs and livers of the mice of the control group and the test group through transmigration and a comparative graph (B) illustrating the number of the melanoma nodules. Referring to FIG. 17, the degree of spread of melanoma in the test group treated with the
polypeptide of the present invention was reduced to about 40% of that of the control group.
Industrial Applicability A polypeptide or its fusion protein according to the present invention can inhibit the transmigration of leukocytes or the growth and/or metastasis of cancer cells.
Claims
[I] A polypeptide consisting of 4 - 130 amino acids derived from the peptide of SEQ ID NO: 1, said polypeptide comprising an amino acid sequence from position 94 to position 97 of SEQ ID NO: 1; wherein said polypeptide inhibits transmigration of leukocytes or growth and/or metastasis of cancer cells.
[2] The polypeptide of claim 1, which is selected from the group consisting of polypeptides as set forth in SEQ ID NOs: 2-8.
[3] The polypeptide of claim 1, which is selected from the group consisting of polypeptides as set forth in SEQ ID NOs: 9-11 and 13-16.
[4] A fusion protein wherein a polyhistidine (poly-His) region is fused to the polypeptide of any one of claims 1 through 3.
[5] The fusion protein of claim 4, wherein the poly-His region has an amino acid sequence as set forth in SEQ ID NO: 17.
[6] A polynucleotide encoding the polypeptide of any one of claims 1 through 3.
[7] The polynucleotide of claim 6, which is selected from the group consisting of polynucleotides as set forth in SEQ ID NOs: 18-20 and 22-25.
[8] A vector comprising a polynucleotide encoding the polypeptide of any one of claims 1 through 3.
[9] The vector of claim 8, wherein a cDNA encoding a poly-His region is inserted.
[10] A transformant obtained by transforming a host cell with the vector of claim 8.
[II] The transformant of claim 10, wherein the host cell is selected from cells of microorganisms belonging to the genus Escherichia and the genus Pichia.
[12] A pharmaceutical composition for the prevention or treatment of inflammatory diseases, comprising the polypeptide of any one of claims 1 through 3 as an active ingredient and a pharmaceutically acceptable carrier.
[13] A pharmaceutical composition for the prevention or treatment of inflammatory diseases, comprising, as an active ingredient, a fusion protein wherein a poly-His region is fused to the polypeptide of any one of claims 1 through 3, and a pharmaceutically acceptable carrier.
[14] A pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells, comprising the polypeptide of any one of claims 1 through 3 as an active ingredient and a pharmaceutically acceptable carrier.
[15] A pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells, comprising, as an active ingredient, a fusion protein in which a poly-His region is fused to the polypeptide of any one of claims 1 through 3, and a pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/991,310 US8207128B2 (en) | 2005-09-28 | 2006-09-20 | Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050090668A KR100758006B1 (en) | 2005-09-28 | 2005-09-28 | Polypeptide having inhibitory activity for angiogenesis and inflammation and a pharmaceutical composition comprising the polypeptide |
KR10-2005-0090668 | 2005-09-28 | ||
KR1020060060890A KR100793947B1 (en) | 2006-06-30 | 2006-06-30 | Polypeptides or fusion proteins thereof having an inhibitory activity against growth and metastasis of cancer cells |
KR10-2006-0060890 | 2006-06-30 | ||
KR1020060067440A KR100793949B1 (en) | 2006-07-19 | 2006-07-19 | Polypeptides or fusion proteins thereof having preventive or treating activity against inflammatory diseases |
KR10-2006-0067440 | 2006-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007037601A1 true WO2007037601A1 (en) | 2007-04-05 |
Family
ID=37899983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2006/003728 WO2007037601A1 (en) | 2005-09-28 | 2006-09-20 | Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof |
Country Status (2)
Country | Link |
---|---|
US (1) | US8207128B2 (en) |
WO (1) | WO2007037601A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011049289A2 (en) | 2009-10-23 | 2011-04-28 | (주) 수파드엘릭사 | Polypeptide or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis of cancer cells |
ITMI20091994A1 (en) * | 2009-11-13 | 2011-05-14 | Istituto Ortopedico Rizzoli | ANTICORPAL FRAGMENT OF THE SINGLE CHAIN VARIABLE REGION (SCFV) ABLE TO RECOGNIZE AND BIND THE HUMAN PROTEIN CD99 |
WO2021118212A1 (en) * | 2019-12-11 | 2021-06-17 | 강원대학교산학협력단 | Pharmaceutical composition comprising peptide that inhibits interaction of p53 and foxo4 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102297396B1 (en) * | 2020-07-29 | 2021-09-06 | (주)티카로스 | Immune Synapse-Stabilizing Chimeric Antigen Receptor(CAR) T Cell |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2402530A1 (en) * | 2000-03-13 | 2001-09-20 | Cornell Research Foundation, Inc. | Blocking leukocyte emigration and inflammation by interfering with cd99 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO2001055208A1 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
EP1436318A2 (en) * | 2001-09-05 | 2004-07-14 | Enkam Pharmaceuticals A/S | Ncam binding compounds |
-
2006
- 2006-09-20 US US11/991,310 patent/US8207128B2/en not_active Expired - Fee Related
- 2006-09-20 WO PCT/KR2006/003728 patent/WO2007037601A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2402530A1 (en) * | 2000-03-13 | 2001-09-20 | Cornell Research Foundation, Inc. | Blocking leukocyte emigration and inflammation by interfering with cd99 |
Non-Patent Citations (3)
Title |
---|
DATABASE GENPEPT [online] 2 June 1997 (1997-06-02), XP003008891, Database accession no. (AAB58501) * |
SCHENKEL A.R. ET AL.: "CD99 plays a major role in the migration of monocytes through endothelial junctions", NAT. IMMUNOL., vol. 3, no. 2, February 2002 (2002-02-01), pages 143 - 150, XP009006021 * |
SCOTLANDI K. ET AL.: "CD99 engagement: an effective therapeutic strategy for Ewing tumors", CANCER RES., vol. 60, no. 18, 15 September 2000 (2000-09-15), pages 5134 - 5142, XP003008890 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011049289A2 (en) | 2009-10-23 | 2011-04-28 | (주) 수파드엘릭사 | Polypeptide or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis of cancer cells |
EP2491944A2 (en) * | 2009-10-23 | 2012-08-29 | Supadelixir Inc. | Polypeptide or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis of cancer cells |
CN102711792A (en) * | 2009-10-23 | 2012-10-03 | 舒帕得力克瑞股份有限公司 | Polypeptide or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis of cancer cells |
JP2013507954A (en) * | 2009-10-23 | 2013-03-07 | スパデリクサー インコーポレイテッド | Polypeptide or fusion protein thereof that suppresses leukocyte extravasation or cancer cell growth and / or metastasis |
EP2491944A4 (en) * | 2009-10-23 | 2013-09-11 | Supadelixir Inc | Polypeptide or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis of cancer cells |
EP2692353A2 (en) | 2009-10-23 | 2014-02-05 | Supadelixir Inc. | Peptide LGD or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis |
EP2692353A3 (en) * | 2009-10-23 | 2014-03-26 | Supadelixir Inc. | Peptide LGD or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis |
ITMI20091994A1 (en) * | 2009-11-13 | 2011-05-14 | Istituto Ortopedico Rizzoli | ANTICORPAL FRAGMENT OF THE SINGLE CHAIN VARIABLE REGION (SCFV) ABLE TO RECOGNIZE AND BIND THE HUMAN PROTEIN CD99 |
WO2011058517A1 (en) * | 2009-11-13 | 2011-05-19 | Istituto Ortopedico Rizzoli | Single-chain variable fragment (scfv) able to recognize and bind cd99 human protein |
US8710194B2 (en) | 2009-11-13 | 2014-04-29 | Istituto Ortopedico Rizzoli | Single-chain variable fragment (scFv) able to recognize and bind CD99 human protein |
WO2021118212A1 (en) * | 2019-12-11 | 2021-06-17 | 강원대학교산학협력단 | Pharmaceutical composition comprising peptide that inhibits interaction of p53 and foxo4 |
Also Published As
Publication number | Publication date |
---|---|
US20100286064A1 (en) | 2010-11-11 |
US8207128B2 (en) | 2012-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5928893A (en) | Monoclonal antibody specific for human 4-1BB and cell line producing same | |
AU710160B2 (en) | Cytokine designated Lerk-7 | |
US7750138B2 (en) | Angiogenesis-inhibiting chimeric protein and the use | |
CA2059124C (en) | Platelet aggregation inhibitors | |
US5668104A (en) | Hematopoietic stem cell growth-promoting compositions containing a fibroblast-derived fragment of fibronectin and a growth factor, and methods employing them in vitro or in vivo | |
US5840869A (en) | DNA encoding interleukin-4 receptors | |
US7659385B2 (en) | Polynucleotides encoding molecules designated LDCAM | |
EP1375518B1 (en) | Anti-osteopontin antibody and use thereof | |
Pochon et al. | Demonstration of a second ligand for the low affinity receptor for immunoglobulin E (CD23) using recombinant CD23 reconstituted into fluorescent liposomes. | |
NZ297530A (en) | Cyclic peptides that inhibit the interaction of vascular cell adhesion molecule 1 (VCAM-1) and fibronectin with integrin very late antigen 4 (VLA-4) | |
JPH08505628A (en) | Peptide type cell adhesion inhibitor | |
US8207128B2 (en) | Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof | |
US8530421B2 (en) | Isolated polypeptides used for treatment of inflammatory diseases and inhibiting cancer metastasis | |
JP2002528389A (en) | Anti-inflammatory peptides derived from IL-2 and analogs thereof | |
CN105916883B (en) | Bifunctional fusion proteins and its preparation method and application | |
MXPA03003008A (en) | Chemokine mutants in the treatment of multiple sclerosis. | |
US20110189181A1 (en) | Use of agents derived from CEACAM1 for the treatment of inflammatory diseases | |
WO1996022106A1 (en) | Cd8 antagonists | |
CA1280379C (en) | Peptides and compositions | |
KR100793949B1 (en) | Polypeptides or fusion proteins thereof having preventive or treating activity against inflammatory diseases | |
WO1994009132A1 (en) | Human cd26 and methods for use | |
JP2003518940A (en) | Nucleic acids encoding (poly) peptides having CHIPS activity | |
US20100197576A1 (en) | Polypeptides or fusion proteins thereof inhibiting transmigration of leucocytes or growth and/or metastasis of cancer cells | |
JP2003500055A (en) | IL-1 eta DNA and polypeptides | |
WO1996040774A1 (en) | Complexes of modified lymphotoxins as pharmaceutical preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11991310 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06798811 Country of ref document: EP Kind code of ref document: A1 |